NeuRX DPS FDA approved ALS More Than a Power Play ALS More Than a Power Play ALS A Prion Disease ALS A Prion Disease MRI Make That A Double MRI Make That A Double Ubqln2 ALS Gene the 13th Ubqln2 ALS Gene the 13th Ubqln2 ALS Gene the 13th TAF15 Going On More Than 16 TAF15 Going On More Than 16 TAF15 Going On More Than 16 TAF15 Going On More Than 16 Empower Gathers Steam Empower Gathers Steam Empower Gathers Steam Spotlight Spotlight Spotlight antiCD40L antiCD40L antiCD40L TDP 43 Targets Emerge TDP 43 Targets Emerge TDP 43 Targets Emerge Dexpramipexole Dexpramipexole Dexpramipexole Dishing ALS Dishing ALS NP001 NP001 NP001 Silence Is Not Golden Silence Is Not Golden

With the drop of the ball, the clinks of champagne glasses and the last fireworks exploded, the year 2011 drew to a close.  Lest the auld year be forgot, ALS TODAY turns back the clock to toast the achievements and innovations in ALS in 2011.

The banner year marked the advancement of a number of cutting-edge ALS treatment strategies to phase II and phase III clinical trials and the introduction of innovative trial designs and analysis tools that promise to expedite the evaluation of these potential medicines.  Innovations in reprogramming technologies continued to push forward the possibility of personalized medicine for people with ALS.  And a new online disease registry fired up, enabling ALS researchers to unravel the genetic and environmental influences that contribute to the disease. Take a look back at ALS in 2011 by exploring this interactive timeline.